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ELIC, the pentameric ligand-gated ion channel from Erwinia chrysanthemi, is a prototype for 
Cys-loop receptors. Here we show that acetylcholine is a competitive antagonist for ELIC. 
We  determine  the  acetylcholine–ELIC  cocrystal  structure  to  a  2.9-Å  resolution  and  find 
that acetylcholine binding to an aromatic cage at the subunit interface induces a significant 
contraction of loop C and other structural rearrangements in the extracellular domain. The side 
chain of the pore-lining residue F247 reorients and the pore size consequently enlarges, but the 
channel remains closed. We attribute the inability of acetylcholine to activate ELIC primarily to 
weak cation-π and electrostatic interactions in the pocket, because an acetylcholine derivative 
with a simple quaternary-to-tertiary ammonium substitution activates the channel. This study 
presents a compelling case for understanding the structural underpinning of the functional 
relationship between agonism and competitive antagonism in the Cys-loop receptors, providing 
a new framework for developing novel therapeutic drugs. 
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C
ys-loop receptors, including nicotinic acetylcholine recep-
tors (nAChRs) and serotonin, glycine and gamma-aminobu-
tyric acid type A (GABAA) receptors, mediate fast chemical 
to electrical transduction throughout the nervous system and are 
important therapeutic targets for many diseases1–7. These receptors 
share a common structural architecture: five homo- or heteromeric 
subunits form a channel; each subunit has an extracellular (EC) 
domain, a transmembrane (TM) domain consisting of four mem-
brane-spanning helices (TM1–TM4) and an intracellular domain 
connecting TM3 and TM4. TM2 lines the lumen of the channel that 
opens on ligand binding in the EC domain. Although mechanisms 
linking ligand binding to channel opening have been proposed on 
the basis of several elegant studies8–11, structural elucidation of this 
allosteric process remains a great challenge.
Three main sources of information have contributed to the struc-
tural understanding of these pentameric ligand-gated ion channels 
(pLGICs). The first consists of crystal structures of ligand-binding 
domains, including acetylcholine-binding proteins (AChBPs)12–17 
and the EC domains of a mouse α1-nAChR18 and an α7nAChR–
AChBP  chimera19.  These  structures  provided  valuable  informa-
tion for ligand binding and the resulting conformational changes 
in the EC domain, but lacked the functionally critical membrane- 
spanning or pore-forming domains. The second source is a 4-Å-
resolution electron microscopy structure of the Torpedo nAChR 
without ligands, representing a closed-channel state20. The third 
source includes the recently solved crystal structures of prokaryotic   
pLGICs from Erwinia chrysanthemi (ELIC)21 and Gloebacter violaceus 
(GLIC)22,23, and eukaryotic Caenorhabditis elegans glutamate-gated 
chloride channel-α24. They share a similar structural scaffold to   
the  EC  and  TM  domains  of  Cys-loop  receptors;  each  structure   
represents a different functional state, but none of these proteins 
have both open and closed structures solved.
The previous apo–ELIC structure resolved at 3.3 Å21 exhibits a 
closed pore in a non-conducting state. A group of primary amines, 
including cysteamine used in this study, was recently identified as 
agonists of ELIC25. Although high-resolution structures of the ago-
nist-bound ELIC have not been resolved, agonist binding in ELIC 
is expected to be at the orthosteric site, based on the anomalous 
difference map of an ELIC–bromopropylamine complex and the 
functional data of several mutants25. Single channel electrophysi-
ology analysis25 confirmed that, similar to nAChRs, ELIC carries 
cation currents. However, ELIC cannot be activated by acetylcho-
line (ACh), an endogenous agonist for nAChRs.
Here we show for the first time the competitive antagonism of 
ACh in ELIC, and the structure of ELIC cocrystallized with ACh 
at a resolution of 2.9 Å. We found that, as a competitive antagonist 
for ELIC, ACh induced the conformational rearrangements in the 
EC domain resembling those observed in the agonist-bound ACh-
BPs13,14,17  and  α7nAChR–AChBP  chimera19.  ACh  binding  not 
only changed the ELIC conformation in the EC domain, but also 
in the TM pore region. The pore size at the hydrophobic restric-
tion region was enlarged, but was not large enough to open the 
channel. It appears that ACh binding brings ELIC to the verge of 
activation. Indeed, a simple substitution from –CH3 to –H in the 
ACh’s choline group was sufficient to convert the ligand from a 
competitive antagonist into an agonist. A comparison of our ELIC 
structures with and without a bound ACh highlights the impor-
tance of cation-π and other electrostatic interactions in the ligand 
binding and channel activation process. Moreover, the structural 
comparison revealed signal propagation underlying ELIC function. 
Because cocrystallization of ELIC with high concentration agonists 
is likely to produce ELIC crystals in a desensitized state, our crys-
tal structure of the ACh–ELIC complex at the verge of activation 
offers a useful template for delineating structure–function relation-
ships of Cys-loop receptors in action. The high-resolution picture of 
ACh binding and the insights into the structural underpinning of   
agonism versus competitive antagonism are instrumental for design-
ing new therapeutic drugs with optimized atomic interactions that 
can potentially suppress or enhance certain conformational states, 
thereby modulating the functions of Cys-loop receptors and alike.
Results
Acetylcholine competitively antagonizes ELIC currents. ACh did 
not activate ELIC, but rapidly and reversibly inhibited the current 
elicited  by  cysteamine  (Fig.  1).  The  concentration-dependent 
inhibition  curves  were  fit  to  the  Hill  equation  and  yielded  an   
ACh IC50 of 0.55 and 1.4 mM at cysteamine concentrations near 
EC10 and EC60, respectively. ACh reduced the apparent affinity of 
cysteamine to ELIC. As depicted in Fig. 1c, ACh shifted the EC50 
of  cysteamine  concentration–response  curves  to  higher  values, 
but did not change the efficacy of cysteamine activation of ELIC, a 
strong indication of competitive antagonism. The ACh dissociation 
constant,  Kb,  was  determined  to  be  2 mM  from  the  Schild  plot   
(Fig. 1c, inset).
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Figure 1 | Acetylcholine inhibition of ELIC. (a) Representative current 
traces in the presence of 0.3 mm cysteamine and the indicated 
concentrations of acetylcholine (ACh). (b) Inhibition of cysteamine-
induced ELIC currents by ACh. Response is expressed as the fraction of 
current induced in the presence of the indicated concentrations of ACh 
and 0.3 mm cystamine (solid circle) or 1 mm cysteamine (solid square) 
relative to that in the absence of ACh. The data are fit to the Hill equation. 
(c) Concentration–response curves for cysteamine in the presence of 0 
(open circle), 0.3 (solid diamond), 1 (solid circle) and 3 (solid square) mm 
ACh. The data are globally fit to a Gaddum/schild nonlinear regression 
with a slope of 1. The schild plot (inset) is also consistent with a slope of 1 
(R2 = 0.92). All data are reported as the mean ± s.e.m. from n≥7 oocytes.ARTICLE     
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The  acetylcholine-binding  pocket.  We  crystallized  ELIC  in  the 
presence and absence of ACh and solved structures to a resolu-
tion of 2.9 and 3.1 Å, respectively. Well-defined electron densities 
were found for ACh in all subunits (Fig. 2). To minimize arte-
facts in structural comparisons, the same method and procedures 
were used in the crystallization and structural refinement for the   
apo- and the ACh-bound ELIC. Table 1 summarizes the statistics 
of data collection and structure refinement. The refined ACh–ELIC 
structure in Fig. 2 shows ACh binding in a site equivalent to the 
orthosteric ligand site in Cys-loop receptors.
Figure 3 depicts the atomic details of the binding pocket. ACh 
is in direct contact (within 4 Å) with residues from loop A (E77, 
I79), loop B (E131, P132, F133) and loop C (Y175, L178, F188) on 
the principal side, and residues from loop D (Y38), loop E (N103) 
and loop G (F19) on the complementary side. ACh is framed in an 
aromatic cage, which is a general feature found in the structures of 
AChBPs and the ligand-binding domain of nAChRs12–20. Figure 4 
exhibits a few examples of residues comprising the aromatic cage. 
ELIC, nAChR and AChBP have four to five aromatic residues to 
comprise an aromatic cage. In contrast, GLIC has only one aro-
matic residue in the principal side. The necessity of having adequate 
aromatic residues for the ligand binding was also corroborated by 
our attempt to cocrystallize GLIC with ACh. Although we used 
the same ACh concentration as used for ELIC crystallization and 
solved the GLIC structure to a resolution of 3.1 Å (data not shown), 
no bound ACh was detected. The overall pocket-lining residues in 
ELIC more closely resemble those in the glycine and GABAA recep-
tors. A sequence alignment of ELIC with several Cys-loop recep-
tors is provided in Supplementary Fig. S1. The negatively charged 
residues do not exist in the ligand pocket of AChBPs and nAChRs, 
but are present in some subtypes of glycine and GABAA receptors. 
E131 in ELIC is equivalent to a conserved glutamate residue (β2-
E155) in the GABAA receptors, which is critical in coupling ligand 
binding to channel gating26. E131 and E77 are close to the positively 
charged quaternary ammonium of ACh, forming favourable elec-
trostatic interactions (Fig. 3). Aromatic residues lining the pocket 
on the principal side are close enough to the choline group for 
potential cation-π interactions. F19 and Y38 on the complementary 
side provide hydrophobic contacts for the acetyl group of ACh. All 
these interactions contribute to the stabilization of ligand binding 
in ELIC. Several specific features in the ELIC ligand pocket, how-
ever, may account for the inability of ACh to activate the channel. 
First, the residue equivalent to I79 in loop A of ELIC is a tyrosine 
residue in the nAChR family (Supplementary Fig. S1). The hydroxyl 
of this tyrosine in AChBPs and the α7-AChBP chimera provides a 
hydrogen-bond interaction with ligands13,14,19. Mutation of an aro-
matic residue to a non-aromatic or different aromatic residue in the 
orthosteric ligand pocket of nAChRs resulted in dramatic reduc-
tions in the apparent ligand affinities and channel activation27,28. 
Second, the carbonyl oxygen of F133 in the ELIC structure is fur-
ther away from the C2 atom of the positively charged choline group 
(3.6 Å) than the distance (3.1 Å) for the CH–O hydrogen bond found 
in the ligand-bound AChBPs13, indicative of a weaker hydrogen 
bond. Third, while the distances (4.7–4.8 Å) between the quaternary 
ammonium of ACh and the aromatic rings of Y175 and F188 are 
similar to those found in the structure of the ACh-bound AChBP17, 
F133’s aromatic ring is much further away from ACh (5.7 Å) than 
is the homologous residue W143 (4.5 Å) in ACh–AChBP17, pre-
senting an overall weaker cation-π interaction. Moreover, having a 
tryptophan residue at the equivalent F133 position was suggested 
to be much more critical than other aromatic positions to ensure a 
strong cation-π interaction and a high ligand-binding affinity28,29. 
Taken together, our high-resolution structural data explain why the   
ACh  binding  to  the  homologous  orthosteric  ligand  site  cannot   
activate ELIC.
To test whether the shielded cation of ACh, unable to make 
effective cation-π and electrostatic interactions in the ELIC pocket,   
is the primary reason for the inability of ACh to activate ELIC,   
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Figure 2 | The 2.9-Å-resolution structure of ELIC bound with five ACh molecules. (a) A side view of the structure with the red surface representing ACh 
molecules. It is notable that the long axis of ACh is almost perpendicular to the channel axis. A pair of principal and complementary subunits for ACh 
binding is depicted in yellow and cyan, respectively. (b) A stereo view of the 2Fo-Fc electron density map, contoured at 1.0 σ-level, for the ACh binding 
site. (c) The Fo-Fc omit electron density maps contoured at different σ-levels with a carve distance of 1.8 Å for ACh molecules shown in the densities as  
red sticks.ARTICLE
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we performed functional measurements on ELIC with a derivative 
of ACh, 2-dimethylaminoethylacetate. This compound differs only 
slightly from ACh, having a hydrogen atom substitution for one of 
the three methyl groups in the quaternary ammonium at neutral 
pH. The substitution exposes the cationic centre of the ammonium 
(Supplementary Fig. S2). Consistent with our prediction, this ACh 
derivative alone elicited ELIC currents (Supplementary Fig. S3). 
A  reversed  shift  from  agonism  to  antagonism  was  observed  for 
the glycine and GABA receptors when the primary amines of the   
glycine or GABA receptor agonists were methylated to tertiary or 
quaternary amines30,31.
A structural superimposition of ELIC and AChBP13 reveals that 
ligands in these two proteins are oriented differently (Supplemen-
tary Fig. S4). Despite a similar position of their cationic centres, the 
acetyl group of ACh in ELIC and the carbamoyl group of carbamyl-
choline in AChBP point in different directions as if one was rotated 
~90° away from the other. With respect to membrane normal, the 
molecular long axis of ACh is oriented nearly perpendicularly in 
the pocket of ELIC, whereas ligands in AChBPs and nAChR are   
oriented  more  parallel  to  the  membrane  normal13–17,19.  Differ-
ent  ligand  orientations  in  ELIC  and  AChBP  provide  additional   
templates for elucidating ligand binding in various pLGICs.
ACh induced changes in the ligand-binding domain. A compari-
son of the apo– and ACh–ELIC structures revealed conformational 
changes near the ligand-binding site, particularly in loop C. Super-
position of these two structures showed that the backbone of loop 
C contracted substantially to wrap the ligand, moving the tip of 
loop C by ~6 Å (Fig. 5a). The side chain of L178 rotated to face ACh   
(Fig. 5a). In addition to the conformational changes, loop C also 
showed reduced flexibility on ligand binding. In the apo–ELIC, the 
averaged B-factor for loop C (157 Å2) is 47 Å2 greater than that for 
the whole protein. For ACh–ELIC, however, the difference is only 
15 Å2. Interestingly, although ACh acts as a competitive antagonist for 
ELIC, its impact on loop C resembled changes induced by the ago-
nist binding in AChBPs and α7nAChR13,14,17,19, suggesting that the 
changes in loop C alone do not distinguish antagonism from agonism.
Residues  on  the  principal  side  of  the  ligand-binding  pocket   
experienced  larger  conformational  changes  than  those  on  the   
complementary side (Fig. 5b,c). In the ACh–ELIC structure, the 
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Figure 3 | Stereo view of atomic details of the ACh-binding pocket. 
Dashed lines indicate distances in Å between the nitrogen atom of the 
positively charged quaternary ammonium of ACh and the relating residues 
for electrostatic interactions or potential cation-π interactions. Residues on 
the principal and complementary sites of the pocket are coloured in yellow 
and cyan, respectively. note the position of ACh in the aromatic cage and 
that F133 (equivalent to W145 of the α7nACh) is likely too far away from 
the ACh ammonium to form a cation-π interaction.
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Figure 4 | Comparison of aromatic residues lining the ligand-binding 
pocket. (a) ELIC determined in this study (PDB code: 3RQW); (b) the 
muscle-type nAChR between α- and γ-subunits (PDB code: 2BG9);  
(c) Ls-AChBP (PDB code: 1uV6); and (d) GLIC (PDB code: 3EAm). The 
principal subunit is coloured in yellow with side chains in orange and the 
complementary subunit is coloured in marine with side chains in purple.
Table 1 | Data collection and refinement statistics.
Apo–ELIC ACh–ELIC
Data collection
  space group P21 P21
  Cell dimensions
    a, b, c (Å) 105.3, 267.0, 111.1 105.8, 266.1, 111.2
    α, β, γ (Å) 90.0, 107.5, 90.0 90.0, 107.8, 90.0
  Resolution (Å)* 29.8–3.09 (3.25–3.09) 29.8–2.91 (3.07–2.91)
  Rmerge* 5.5 (65.1) 4.4 (74.3)
  I/σI* 15.0 (2.2) 22.1 (2.0)
  Completeness (%)* 97.4 (91.6) 98.0 (94.9)
  Redundancy * 3.8 (3.8) 3.9 (4.0)
Refinement
  Resolution (Å) 25.0–3.09 25.0–2.91
  no. of reflections 97,441 117,512
  Rwork/Rfree 20.9/24.0 20.6/23.1
  No. of atoms
    Protein 25,050 25,050
    Ligand — 100
    solvent† 258 358
  B-factors
    Protein 109.8 96.6
    Ligand — 69.5
    solvent† 119.4 114.2
  R.m.s deviations
    Bond lengths (Å) 0.006 0.008
    Bond angles (Å) 1.0 1.1
  PDB codes 3RQu 3RQW
*Values in the parentheses are for highest-resolution shell.
†solvent includes water, glycerol and mEs buffer molecules.ARTICLE     
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aromatic rings of Y38 and F19 barely shifted towards the ligand 
(Fig. 5c), but E131 of loop B, Y175 and F188 of loop C deviated sig-
nificantly from their positions in the apo–ELIC structure (Fig. 5b). 
E77 and I79 of loop A had only minor reorientations in their side 
chains. It was predicted that residues equivalent to F133 and Y175 
in the α1nAChR (W149 and Y190) would change their respective 
positions on ligand binding to trigger the forward cascade of chan-
nel gating11. In ELIC, similar to the α7nAChR–AChBP chimera19, 
F133 of loop B remained the same in the apo– and ACh–ELIC 
structures.  In  contrast,  Y175  moved  downward  and  produced  a 
domino effect on E129 and E131 of loop B and R190 of β10. All of 
these residues shifted towards the TM domain through side chain 
electrostatic interactions (Fig. 5d). It is worth noting that Y175, 
E129 and I79 in the ACh–ELIC structure do not have close contact, 
unlike the equivalent residues in the structures for the epibatidine-
bound α7nAChR–AChBP chimera (Y184, K141 and Y91)19 and the 
nicotine-bound AChBP (Y185, K139 and Y89)13. In those struc-
tures, the side chains of residues homologous to Y175 and E129 
form a hydrogen bond on agonist binding13,19. Here the interaction 
between Y175 and E129 is mediated by E131 and R190.
Collectively, the aforementioned changes in ELIC lead to a con-
certed rotation in the EC domain on ACh binding (Fig. 6). When 
viewed from the top of the pentameric structure, loops B and C 
in the upper portion of the EC domain show a counterclockwise   
rotation,  while  loop  F  and  β-10  in  the  lower  region  of  the  EC 
domain exhibit a clockwise rotation. A similar concerted rotation 
induced by ligands was observed in the ligand-bound structures of 
AChBP14,15 and the α7nAChR–AChBP chimera19.
The pore region. ACh binding introduced substantial conforma-
tional changes in the EC domain. Did these changes affect the pore 
region? The domino effect initiated by the pocket residues Y175 and 
E131 extended to E129 of loop B and propagated further down to 
the so-called ‘Cys’ loop. This loop is homologous to the Cys loop in 
nAChRs, but without cystine residues. Several residues in the ‘Cys’ 
loop, such as the conserved residues D122 and P120, showed differ-
ent degrees of reorientation in their side chains (Fig. 7a). The salt 
bridge between D122 and R199 (pre-TM1) was weakened due to 
reorientation of the D122 side chain. Conversely, the residues in the 
β1–β2 linker were less affected and the nearby TM2–TM3 linker 
remained almost unchanged.
Inside the pore, the side chain of the hydrophobic constriction 
residue F247 is rotated slightly away from the pore centre (Fig. 7b,c). 
Compared with the apo structure, the pore diameter near F247 in 
the ACh–ELIC structure is enlarged by ~1.32 Å (Fig. 7d). This side 
chain rearrangement is favourable for water as well as ion passage, 
but the pore size is not enlarged enough to remove the hydropho-
bic restriction to ensure a conducting channel. Consistent with our 
functional measurements, our molecular dynamics simulations on 
the ACh–ELIC structure demonstrated that the region between the 
two hydrophobic rings of F247 and L240 inside the pore was dehy-
drated (Supplementary Fig. S5). It appears that a more substantial 
backbone rearrangement of the pore, such as radial or lateral tilt of 
the TM2 helices, is required to open the channel.
Discussion
The crystal structure of ACh–ELIC solved in this study provides 
by far the highest resolution image for ligand binding in ELIC. 
The ACh pocket in the structure mirrors conserved features of the 
ligand-binding core in Cys-loop receptors, especially those in the 
glycine and GABA receptors with more conserved pocket-lining 
residues32. Because of the sequence similarity in the ligand-binding 
EC domain, the gene encoding ELIC has been annotated as a GABA 
receptor homologue, even though ELIC is a cation, instead of anion, 
channel. Indeed, GABA activates ELIC at mM concentrations25. 
The ligand-bound ELIC structure is thus particularly valuable for 
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Figure 5 | The conformational changes in and near the ACh-binding 
pocket. The apo– and ACh–ELIC structures are coloured in green and 
orange, respectively. structural superposition reveals conformational 
changes in several regions. (a) Loop C contracted substantially after ACh 
binding. note that the L178 side chain is turned towards ACh.  
(b) Conformational changes in the principal face of the binding site.  
(c) Conformational changes in the principal face prompted by ACh binding 
are much more profound than those in the complementary face. (d) The 
Y175 downward movement driven by ACh binding has produced a domino 
effect, moving E131, R190 and E129 towards the EC–Tm interface through 
side chain electrostatic interactions. For clarity, a and d show only the 
backbone structure of ACh–ELIC except for loop C in a and side chains  
in d, where both apo– and ACh–ELIC structures are presented. ACh is 
depicted in a purple surface.
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β10
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Figure 6 | ‘Twist’ motion in the extracellular domain on ACh binding. 
Backbone superposition of the apo–ELIC (green) and the ACh–ELIC 
(orange) structures indicates a ‘twist’ motion. several loops at the top 
half of the EC domain, including most visible loop C and loop B, show a 
counterclockwise rotation. Loop F and β10 at the bottom of the EC domain 
exhibit a clockwise rotation. ACh is shown in a purple surface. ARTICLE
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understanding  ligand  recognition  in  inhibitory  neurotransmitter 
receptors.
ACh acts as a competitive antagonist for ELIC, yet its binding 
mode displayed in the structure resembles what has been suggested 
by the anomalous signal calculated at 5 Å for the ELIC agonists25. 
Residues lining the ACh pocket are the same residues embracing 
agonists. Mutating these residues has functional consequences in 
ELIC25. The ACh cationic centre is adjacent to the carboxyl groups 
of E131 and E77, where ELIC agonists are also expected to place 
their primary ammonium25. The position of the cationic choline 
group relative to the aromatic rings of Y175, F188 and F133 in the 
ACh–ELIC structure highlights the contribution of cation-π inter-
actions in ligand binding and channel activation. We predict that 
the cationic centre of the smaller primary ammonium of an ELIC 
agonist is positioned even closer to these aromatic and negatively 
charged residues than that of the choline group in the ACh–ELIC 
structure. The resulting stronger electrostatic interactions do not 
appear  to  significantly  affect  the  binding  affinity,  given  that  the 
apparent  ACh-binding  affinity  of  2 mM  is  comparable  with  the 
affinities for most of the ELIC agonists identified so far. However, 
the more focused charge of the primary ammonium of an ELIC ago-
nist is probably the determinant for inducing the more extensive 
conformational changes required for ELIC activation.
It is interesting to note that ACh, a competitive antagonist for 
ELIC,  induces  conformational  changes  resembling  those  found 
in the agonist-bound structures for AChBPs and the α7nAChR–
AChBP  chimera13,14,19,33.  Significant  contraction  of  loop  C  has 
been viewed as a signature of agonist binding13,14,19. In contrast, 
outward movement of loop C was found in most of the antagonist-
bound AChBPs14,15,34. Our structure demonstrates unambiguously 
that the ACh binding moved loop C inward instead of outward. 
In  addition,  the  reduced  flexibility  of  loop  C  in  the  ACh–ELIC 
structure is in line with the observation that agonist activation of 
the GABAA receptors proceeds through restricting loop C mobil-
ity35. Conformational changes introduced by ACh in other regions 
of the ligand-binding domain in ELIC also resemble the changes 
triggered by agonist binding in AChBPs and the α7nAChR–AChBP 
chimera13,14,19,33, including a concerted rotation in the EC domain 
(Fig. 5).
If ACh is able to produce conformational changes similar to what 
agonists produce in AChBPs, why does ACh act as a competitive 
antagonist instead of an agonist for ELIC? Our structural and func-
tional data suggest that ACh shifts the ELIC conformation much 
in the same way as an agonist, but the extent of the shift is insuf-
ficient for activating the channel. Although multiple factors may 
account for the inability of ACh to elicit currents, lack of an ade-
quate cationic strength to accommodate electrostatic interactions in 
the ELIC ligand pocket appears to be the primary reason. The most 
compelling evidence is the observation of ELIC currents elicited by 
the ACh derivative 2-dimethylaminoethylacetate (Supplementary   
Fig. S3). The fact that a simple removal of a methyl in the choline 
group is sufficient to activate ELIC signifies the importance of the 
ligand cationic group and the critical functional roles of the aromatic 
and negatively charged residues near the ligand cationic group. The 
more exposed positive charge of the ACh derivative (Supplemen-
tary Fig. S2) is likely able to pull the surrounding negatively charged 
residues and aromatic rings closer to the ligand than what has been 
seen in the ACh–ELIC structure. This result is in line with the 
observation that all the ligands identified previously for activating 
ELIC are primary ammonium ions25, which are more energetically 
favourable for forming cation-π interactions36.
Although  further  studies  are  required  to  define  exactly  how   
ligand binding leads to the pore opening in the membrane-span-
ning region, the high-resolution structure of ACh–ELIC, which is 
probably at the verge of channel opening, offers at least some clues. 
First, residues on the principal side of the binding pocket respond to 
ligand-induced conformational changes more sensitively than those 
on the complementary side (Fig. 5). They may have more domi-
nant roles in proceeding signal transduction. Second, because of its 
innate flexibility, loop C moves inward or outward to accommodate 
ligand binding. The ACh–ELIC structure shows that the moving 
direction of loop C alone is not sufficient to determine agonism or 
antagonism of a ligand. Third, an assembly of aromatic and charged 
residues in ELIC (Fig. 5d), including Y175 and R190 of loop C, E131 
of loop B and E129 at the base of the ‘Cys’ loop, is notable for propa-
gating the binding signal from the pocket towards the TM domain. 
E129 and E131 in ELIC are homologous to βE153 and βE155 in the 
GABAA receptors, where both βE153 and βE155 were found critical 
in coupling ligand binding to channel gating26,35. In the muscle-type 
nAChR, Y190 (homologous to Y175 in ELIC) was found to interact 
with K145 (homologous to E129 in ELIC) when an agonist bound to 
the receptor and disrupted the salt bridge between D200 (homolo-
gous to R190 in ELIC) and K145 (ref. 37). It is unclear at the current 
stage whether a direct contact between Y175 and E129 is necessary 
for ELIC activation or not. However, on the basis of the ACh–ELIC 
structure, it is conceivable that a much more substantial structural 
rearrangement, including a further Y175 downward movement or a 
substantial E129 upward movement, is required for these two resi-
dues to have direct contact. Such a rearrangement will subsequently 
make the ‘Cys’ loop connecting to E129 experience a much larger 
conformational change than that presented in the ACh–ELIC struc-
ture. Finally, even in the ACh–ELIC structure where conformational 
changes triggered by ACh are presumably less profound than those 
induced by an agonist, the ‘Cys’ loop has demonstrated engagement 
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Figure 7 | Structural comparison at the EC–TM interface and the 
pore region. The apo– and ACh–ELIC structures are coloured in green 
and orange, respectively. (a) side chains of the residues in the β1–β2 
linker (n27-E30) and the ‘Cys’ loop (L118-D122) are shown in stick 
representation. no discernable changes were observed in the β1–β2 linker. 
All the residues in the ‘Cys’ loop experienced a varying degree of side chain 
reorientation. (b) Top view and (c) side view of the superimposed pore 
region. one subunit was removed in c for clarity. no change was observed 
for the Tm2 helical backbone. The side chain of F247 swung away from 
the pore centre to a small degree, yielding a less restricted pore radius near 
F247, as manifested by the pore radius profiles in d.ARTICLE     
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in ligand signal transduction, whereas the β1–β2 linker has nearly 
none. This observation seems to project a more active role of the 
‘Cys’ loop in mediating ligand-binding signals at the interface of the 
EC and TM domains. It should be noted that this observation by no 
means discounts the possible involvement of the β1–β2 linker in 
transducing the binding signal to the TM domain. It is plausible that 
failure to induce a significant conformational change in this linker is 
one of the reasons why ACh binding cannot activate ELIC. Never-
theless, the insights from this study warrant further structural and 
functional investigations of this region in the near future.
Methods
Protein expression and purification. ELIC was expressed using a plasmid gener-
ously provided by Professor Raimund Dutzler’s group at the University of Zürich, 
Zürich, Switzerland. The procedures for expression and purification were modified 
based on the published protocol21. Rosetta (DE3) pLysS (Novagen) transformed 
with the ELIC plasmid was grown in Luria-Bertani media at 37 °C to an OD600 
of 0.5, transferred to another shaker at 15 °C, and equilibrated for 1–2 h before 
adding isopropyl-β-D-thiogalactoside to 0.2 mM. Cells were collected after 2 days, 
resuspended in buffer A (150 mM NaCl, 50 mM sodium phosphate, pH 8) with 
Halt protease inhibitor cocktail (Thermo Scientific), and lysed with a M-110Y 
microfluidizer processor (Microfluidics). MBP–ELIC was extracted from isolated 
membranes with 3% (wt/vol) n-undecyl-β-D-maltoside (Anatrace) in buffer A and 
purified using Ni-NTA chromatography (GE Healthcare). After overnight digestion 
with HRV3C protease (GE Healthcare), pentameric ELIC was separated from its 
fusion partner MBP using Ni-NTA chromatography, followed by size exclu-
sion chromatography using a Superdex 200 10/300GL column (GE Healthcare) 
in a buffer containing 10 mM sodium phosphate (pH 8), 150 mM NaCl, 0.025% 
(wt/vol) n-dodecyl-β-D-maltoside (Anatrace). The purified ELIC was concentrated 
to ~10 mg ml − 1 for crystallization.
Crystallography and data analysis. Crystallization was achieved using the sit-
ting-drop method at 4 °C. ELIC was pre-equilibrated with 0.5 mg ml − 1 Escherichia 
coli polar lipids (Avanti Polar Lipids) before being mixed in 1:1 ratio with the 
reservoir solution containing 10–12% polyethylene glycol 4000, 200 mM ammo-
nium sulphate, 100 mM MES buffer (pH 6.1–6.3) and 10 mM ACh. Crystals were 
obtained within 1–2 days. For cryo-protection, crystals were soaked briefly in the 
reservoir solution supplemented with 20% glycerol and 50 mM ligand before being 
flash-frozen in liquid nitrogen.
The X-ray diffraction data were acquired on beamline 12-2 at the Stanford Syn-
chrotron Radiation Lightsource (SSRL) and processed with the XDS program.38 
Crystals of the apo– and the ACh–ELIC have the P21 space group with two  
identical pentamers in each asymmetric unit.
The previously published ELIC structure (PDB code: 2VL0, 3.3 Å resolu-
tion) was used as a starting template for the structure determination. A glycine 
residue (G164), which was missing in 2VL0, was added. To minimize model bias, 
Autobuild in Phenix39 was applied to the data of the apo–ELIC (3.09 Å) and the 
ACh–ELIC (2.91 Å) structures. A relatively complete atomic model was generated 
for each data set by iterative model building, refinement and model-based density 
modification40. The obtained model was further refined by Phenix. Non-crystal-
lographic symmetry restraints were applied for the ten subunits in the asymmetric 
unit. Automatic solvent detection, updating and refinement were applied initially 
for placing water molecules. Manual inspection and adjustment were performed at 
later stages.
Finally, ACh molecules were built into those well-defined Fo-Fc densities using 
Coot41. The final structure was obtained after additional refinement cycles. Crystal 
structure analysis was performed using Phenix and CCP4 (ref. 42). All molecular 
graphics were prepared using PyMol43.
Functional measurements. DNA encoding ELIC downstream of a T7 promoter 
was inserted into the vector pCMV-mGFP Cterm S11 Neo Kan (Theranostech), 
and the construct was confirmed by DNA sequencing. Capped complementary 
RNA was synthesized with the mMessage mMachine T7 kit (Ambion), purified 
with the RNeasy kit (Qiagen), and injected (4–25 ng) into Xenopus laevis oocytes 
(stages 5–6). Oocytes were maintained at 18 °C in modified Barth’s solution 
containing 88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 15 mM HEPES, 0.3 mM 
Ca(NO3)2, 0.41 mM CaCl2, 0.82 mM MgSO4, 10 µg ml − 1 sodium penicillin, 
10 µg ml − 1 streptomycin sulphate, 100 µg ml − 1 gentamycin sulphate, pH 6.7. Two-
electrode voltage clamp experiments were performed at room temperature 16–48 h 
after injection. A GeneClamp 500B amplifier (Axon Instruments) and a 20 µl 
oocyte recording chamber (Automate Scientific) were used for the measurements. 
Oocytes were clamped to a holding potential of  − 20 to  − 60 mV. The recording 
solutions contained 130 mM NaCl, 10 mM HEPES, pH 7.0 and their respective lig-
ands. The ACh and cysteamine solutions were prepared fresh for each experiment. 
All solutions containing cysteamine were supplemented with 1 mM dithiothreitol. 
Data were collected and processed using Clampex 10 (Molecular Devices). Nonlin-
ear regressions were performed using Prism software (Graphpad).
Molecular dynamics simulations. NAMD 2.7b1 (ref. 44) and CHARMM-27 force 
field45 were used for molecular dynamics simulations of two systems containing 
the apo- and ACh-bound ELIC. For each system, an ELIC structure was inserted 
into a pre-equilibrated bacterial lipid bilayer (POPE/POPG ~3:1) in a hexagonal 
prism, solvated, and ionized with visual molecular dynamics plugins.46 Each sys-
tem contained one ELIC pentamer, 166 POPE, 53 POPG, 23 Cl − , 106 Na +  or 101 
Na +  with 5 ACh, and about 24,360 TIP3 water molecules. Each system was energy 
minimized for 20,000 steps, warmed up to 310 K over 62 ps at 1 fs per step with  
the backbone restraint of 1 kcal mol − 1 Å − 2 on ELIC. The restraint was gradually  
reduced and removed after 600 ps of simulation. After the equilibration, we 
changed the Langevin damping value from 10 ps − 1 to 1 ps − 1 and the time step to 
2 fs. Both systems were simulated for 40 ns at constant temperature and pressure of 
310 K and 1 atm, respectively. The particle mesh Ewald method (PME) was used for 
long-range electrostatic interactions and a 12-Å cutoff was used for non-bonded 
interactions, which were evaluated at every step. The full electronic interactions 
were evaluated at every other step. Periodic boundary conditions were used in all 
simulations. Pore-radius profiles were computed using the HOLE program.47 
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